{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorder&page=10",
    "query": {
      "condition": "Blood Coagulation Disorder",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 855,
    "total_pages": 86,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorder&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorder&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T07:29:34.863Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07288489",
      "title": "Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Blood Loss, Surgical",
        "Coagulation Disorder"
      ],
      "interventions": [
        {
          "name": "Reltodecacog alfa",
          "type": "DRUG"
        },
        {
          "name": "Usual Pharmacological Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VarmX B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2026-08-18",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 19,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Stanford, California + 14 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288489"
    },
    {
      "nct_id": "NCT03410290",
      "title": "Journey of Patients With Vasculitis From First Symptom to Diagnosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Vasculitis",
        "Systemic Vasculitis",
        "Behcet's Disease",
        "CNS Vasculitis",
        "Cryoglobulinemic Vasculitis",
        "Eosinophilic Granulomatous Vasculitis",
        "Temporal Arteritis",
        "Giant Cell Arteritis",
        "Granulomatosis With Polyangiitis",
        "Wegener Granulomatosis",
        "Henoch Schonlein Purpura",
        "IgA Vasculitis",
        "Microscopic Polyangiitis",
        "Polyarteritis Nodosa",
        "Takayasu Arteritis",
        "Urticarial Vasculitis"
      ],
      "interventions": [
        {
          "name": "Online Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 456,
      "start_date": "2018-01-11",
      "completion_date": "2018-05-21",
      "has_results": false,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03410290"
    },
    {
      "nct_id": "NCT00107913",
      "title": "Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Doxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hematology and Oncology Specialists",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2001-09",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 1,
      "location_summary": "Metairie, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107913"
    },
    {
      "nct_id": "NCT00989196",
      "title": "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Human-cl rhFVIII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Kogenate FS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2010-05",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00989196"
    },
    {
      "nct_id": "NCT03196297",
      "title": "A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Haemostasis",
        "Haemophilia A"
      ],
      "interventions": [
        {
          "name": "Concizumab",
          "type": "DRUG"
        },
        {
          "name": "Turoctocog alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2017-08-16",
      "completion_date": "2020-06-03",
      "has_results": true,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03196297"
    },
    {
      "nct_id": "NCT01271868",
      "title": "Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "IB1001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medexus Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "Up to 12 Years"
      },
      "enrollment_count": 9,
      "start_date": "2010-11",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2021-03-15",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Houston, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01271868"
    },
    {
      "nct_id": "NCT01395810",
      "title": "Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia B"
      ],
      "interventions": [
        {
          "name": "nonacog beta pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "13 Years to 70 Years · Male only"
      },
      "enrollment_count": 71,
      "start_date": "2012-04-15",
      "completion_date": "2014-03-30",
      "has_results": true,
      "last_update_posted_date": "2018-05-09",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395810"
    },
    {
      "nct_id": "NCT03432520",
      "title": "Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "SPK-8011",
          "type": "GENETIC"
        },
        {
          "name": "SPK-8016",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2018-08-14",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2024-11-29",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 9,
      "location_summary": "Boston, Massachusetts • Madison, Mississippi • Kansas City, Missouri + 5 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03432520"
    },
    {
      "nct_id": "NCT05147662",
      "title": "A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment of Bleeding",
        "Prophylaxis of Bleeding",
        "Hemophilia A",
        "Children"
      ],
      "interventions": [
        {
          "name": "Damoctocog alfa pegol (Jivi, BAY94-9027)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "7 Years to 11 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2022-03-23",
      "completion_date": "2025-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05147662"
    },
    {
      "nct_id": "NCT00840086",
      "title": "Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A"
      ],
      "interventions": [
        {
          "name": "turoctocog alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 150,
      "start_date": "2009-04",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-10-24T07:29:34.863Z",
      "location_count": 18,
      "location_summary": "Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00840086"
    }
  ]
}